Estrella-Porter, P., Correcher-Martínez, E., Orrico-Sánchez, A., & Carreras, J. J. (2025). Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign.
Chicago Style CitationEstrella-Porter, Pablo, Elisa Correcher-Martínez, Alejandro Orrico-Sánchez, and Juan J. Carreras. Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis From Spain’s 2023–2024 RSV Immunisation Campaign. 2025.
MLA CitationEstrella-Porter, Pablo, Elisa Correcher-Martínez, Alejandro Orrico-Sánchez, and Juan J. Carreras. Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis From Spain’s 2023–2024 RSV Immunisation Campaign. 2025.
Warning: These citations may not always be 100% accurate.